Shots:

• The company has completed an enrollment in P-III (GLEAM & GLIMMER) clinical trials to evaluate the durability, efficacy and safety of KSI-301 (anti-VEGF antibody biopolymer conjugate) in ~450 patients with DME
• The 1EPs for both studies is at 1yrs. and patients will be treated and followed for 2yrs. The results for P-IIb/III (DAZZLE) study are expected in Q1’22 & for P-III (BEACON) study in mid 2022. The P-III (GLOW) study for non-proliferative diabetic retinopathy is also underway
• KSI-301 is an anti-VEGF therapy built on Kodiak's ABC Platform & has the potential to maintain potent and effective drug levels in ocular tissues. KSI-301 clinical program is being conducted at 150+ study sites in 10+ countries

Ref: PR Newswire | Image: Stock Light